

ABSTRACT

Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, *e.g.*, in a human subject suffering from a disorder in which ghrelin activity is detrimental.